Fillers are the most widely used substances in aesthetic medicine [12] and are a viable alternative to surgery for patients seeking a safe, minimally invasive, and affordable means of maintaining a youthful appearance and correcting facial contour deficiencies[13]. These products have become a staple in aesthetic and medical procedures. A wide variety of options are available on the market, but the mechanisms associated with their effects still need to be fully understood [14]
It is known that the physiological reactions induced by these biomaterials are conditioned by their physical and biochemical properties, patient characteristics, and the injection technique used [15]. To better understand the biological interaction played by fillers, rodent models have proven to be a helpful tool, assessing, in addition to morphological changes in the skin, the lifting capacity, and the resistance to tissue deformation [16].
Traditionally, these experimental models inoculate the biomaterials into the dermal layer [17–20], one of the injection planes used to apply fillers. However, for safety purposes, most practitioners in the clinic use blunt cannulas for the injections, making filling at the dermal level impractical. The injection plane becomes subcutaneous with a blunt cannula, a trend in use today [21]. For this reason, the experimental model standardized in the present study evaluates the effects of the subcutaneous application of fillers.
Rodent skin differs from human skin, which must be considered in experimental studies. In rodents, the epidermis is thin and has a high density of hair follicles. The dermal white adipose tissue is delicate and lies directly beneath the reticular dermis, clearly separated from the subcutaneous white adipose tissue by a muscular layer called the panniculus carnosus [22]. Although many other mammals, including humans, do not have the panniculus carnosus, layers of adipose tissue exist beneath the reticular dermis in several species, including pigs and humans [23]
Considering the proposal of applying fillers at the subcutaneous level, we initiated the development and standardization of our experimental model, evaluating morphological changes in Wistar rats' skin after using hyaluronic acid (HA) and polycaprolactone (PCL). The increasing worldwide demand for soft tissue fillers motivated us to investigate the direct action of these materials on intimal tissue.
Visual inspection of the rat’s skin after euthanasia and histopathological analysis in both periods evaluated confirmed the biocompatibility with no clinical, macro, or microscopic signs of inflammation. The folded skin showed that the HA had a nodular appearance, and its volume appeared to increase after 30 days of biomaterial inoculation. In tissues with PCL, there was volume loss after 30 and 60 days, visually observed right after the Ellansé application. With 70% CMC in its composition, Ellansé, presents a general decrease in volume due to the reabsorption of this vehicle after one month. Connective tissue and neoformed vessels replace approximately 50% of the original CMC volume. The key to maintaining volume after injection of PCL-based filler is the formation of new vessels and collagen deposition [24], as observed in the present study, suggesting the volumizing capacity of PCL is smaller than hyaluronic acid’s capacity.
According to the literature, HA promotes volumization and has an essential hygroscopic function, contributing to volume gain[25]. Histological analysis confirmed the presence of the biomaterials in the subcutaneous tissue below the panniculus carnosus skeletal muscle layer. The HA group showed mild neovascularization and an apparent increase in adipose tissue in the peri-implant region. Some authors consider HA to be minimally immunogenic, making it the most commonly used temporary filler with clinically satisfactory results in terms of volume. In the present study, this fact is corroborated by the increase in the volume of the area that received HA, 30 and 60 days after application. Hyaluronic acid dermal fillers are now considered the preferred material for minimally invasive cosmetic interventions [26]. Because HA does not show specificity for any organ or species, HA is considered immunologically inert [27, 28]. According to papers published in the literature, once injected into the skin, HA causes a mild inflammatory reaction at the host tissue boundary followed by a gradual fibrous growth, which anchors the gel to the surrounding host tissue, preventing product migration [29]. Our macroscopic and histological analyses after 30 and 60 days did not detect any evidence of acute inflammation. We observed that HA induces a discrete formation of fibrous connective tissue, which probably contributes to preventing material displacement. In addition, we observed an increase in adipose tissue at the periphery of the HA; however, no measurements were taken, and further studies are needed to confirm this finding. In 2020, Nadra and colleagues demonstrated in in vitro studies that treatment with cross-linked HA showed beneficial effects on cell adhesion and survival and reduced basal and induced lipolysis in fully mature adipocytes.
In this work, cross-linked HA promoted cell adhesion and preserved the adipogenic capacity of pre-adipocytes during prolonged cell culture, bringing additional evidence of the beneficial role of cross-linked HA-based fillers in maintaining subcutaneous fat. On the other hand, another paper published in 2017 demonstrated that HA promoted the proliferation of adipose tissue-derived stem cells and the differentiation of these cells into adipocytes, suggesting an action of HA related to increasing the number of adipocytes [30]. The presence of adipose tissue associated with PCL, appeared less evident when compared to HA and more apparent when compared to CONTROL. However, further studies are needed to confirm this finding. We found no evidence in the literature to support this finding. When analyzing the PCL samples, we identified, among the particles of the material, intense cell proliferation, and neovascularization, besides deposition of extracellular matrix between the particles and discrete collagen deposition. Some foci of the CMC carrier were also observed at 30 and 60 days. After 60 days, the cellularity decreased, showing an apparent increase in collagen deposition between the particles when compared to the 30-day analysis. There are reports in the literature that the CMC itself, the carrier of the PCL particles, seems to stimulate the tissue reaction until the complete resorption of the biomaterial is found in some giant cells in its periphery [31]. It is well established in the literature that the presence of biomaterial can induce a foreign body reaction, where monocytes migrate into the tissue, becoming macrophages, which, together with platelets, synthesize platelet-derived growth factor (PDGF) and transforming growth factor beta (TGFβ), which promote the migration of fibroblasts [32]. It was observed, through immunohistochemistry for IBA-1, the appearance of a higher number of activated macrophages in the experimental HA and PCL groups when compared to the control group (CONTROL). This increase was more expressive in the 30-day evaluation, with a more significant number of activated macrophages in the samples with PCL compared to HA, and both (HA and PCL) showed greater immunolabeling for IBA-1 when compared to the CONTROL group. There was a significant reduction of activated macrophages in the HA group at 60 days, but the statistical difference concerning the CONTROL group was maintained. The number of activated macrophages in the PCL group remained high after 60 days, and there was no significant difference in IBA-1 immunolabeling between the 30 and 60-day analyses. The higher number of macrophages in this group is probably related to the physical characteristics of the polycaprolactone, which presents as immunologically inert microspheres large enough to induce macrophage aggregation.
As mentioned earlier, macrophages release TGF-β, regulating cell behavior. TGF-β is known to be a potent chemoattractant for endothelial cells and fibroblasts, as well as for cells of innate immunity, such as neutrophils and monocytes[33], TGF-β can be considered an essential physiological regulator both for the maintenance of the extracellular matrix and also in tissue repair processes [34]. In the present study, we observed significant differences in immunostaining for TGF-β between the HA and PCL groups compared to the CONTROL group in the 30 and 60-day analyses. A substantial increase in TGF-β expression was observed in the 60-day analyses in the PCL group compared to HA, which was not observed at 30 days. Immunolabeling was observed mainly in the cytoplasm of macrophages. The significant increase in TGF-β immunolabeling in the PCL group compared to HA after 60 days is related to the higher expression of IBA-1 observed in PCL since the expression of TGF-β by macrophages is well established in the literature. Moreover, the significant increase of fibroblasts in HA and PCL groups, compared to CONTROL, also contributes to understanding the higher expression of TGF-β in these groups. Although macrophages are the primary source of TGF-β, studies demonstrate fibroblasts' expression of this growth factor, especially during repair processes [35], closing a cycle in which TGF-β expressed by macrophages is a potent chemoattractant for fibroblasts, which in turn can express TGF-β.
The present study observed a significant increase in fibroblasts and fibrocytes in the HA and PCL groups compared to CONTROL at the evaluated periods. Fibroblasts are the most abundant cells in the dermis. These cells' essential characteristics are their ability to synthesize and remodel ECM. In a repair process, fillers work as a framework for the proliferation of these cells, which are the primary basis for fibrogenesis [36]. The literature further describes the chemoattractant role of TGF-β for endothelial cells [37]. Our study observed a significant increase in small vessels and capillaries in the HA and PCL groups, 30 days after inoculations compared to CONTROL. In contrast to that observed in HA, The number of vessels in the PCL group remained significantly higher compared to CONTROL even after 60 days. This result can be justified, at least in part, by the maintenance of high TGF-β expression observed in the PCL group even after 60 days. Despite the more significant number of vessels observed in the HA and PCL groups, there were no statistical differences regarding vessel area between the experimental groups, probably due to the small cross-section of the capillaries. We observed increased protein expression, by immunohistochemistry and Western Blot, for fibroblast growth factor (FGF) in both HA and PCL groups compared to the CONTROL group. Fibroblast growth factors (FGFs) are broad-spectrum mitogens and regulate cellular functions, including migration, proliferation, differentiation, and survival. FGF signaling is essential in tissue development, metabolism, and homeostasis [38]. FGF family members increase fibroblast proliferation and activation, stimulating collagen accumulation and angiogenesis, and are essential in tissue repair [39–41].
Our data reinforce these studies since the higher protein expression of FGF was accompanied by a significant increase in fibroblasts, blood vessels, and collagen in tissue inoculated by both fillers evaluated. Collagen deposition was assessed in the connective tissue adjacent to the HA and PCL mass by Picrosirius Red staining under polarized light. There was a more significant deposition of collagen III, at 30 days, in PCL compared to HA, probably related to the increase of FGF already in this period. In 60 days, there was a significant reduction of collagen III in groups HA and PCL compared to the previous period, with no significant difference between HA and PCL. When type I collagen was evaluated, there were no differences between HA and PCL in the periods considered. It is known that collagen is the dominant component of the ECM in the dermis and accounts for approximately 70% of its dry weight.
Furthermore, in intact adult skin, the ratio of collagen I to collagen III is approximately 4: 1. The amount of collagen III increases temporarily when the skin is injured and during neoderm formation. In freshly healed human skin, the ratio of collagen I to collagen III is about 1: 1, as in neonatal skin. At the same time, in response to a wound, the skin may have a higher amount of collagen III and hyaluronic acid and a lower amount of collagen I [42]. The higher amount of collagen III observed in our analyses is probably associated with the natural tissue repair and healing process, which initially forms collagen III.
In 2014, Kim and colleagues investigated whether PCL-based dermal filler induced neocollagenesis in human tissue in a pilot study by histological analysis. Two patients indicated for temple lift surgery were included in the study. PCL was injected intradermally into the temporal region, just below the hairline, which would be included in lift surgery, 13 months after injection. Tissue collected after surgery showed collagen formation around the PCL particles, maintained even 13 months after injection [31].
Another study compared neocollagenesis and elastin production stimulated by Radiesse® (calcium hydroxylapatite; CHAA, Merz Pharmaceuticals GmbH) and Juvéderm® VOLUMA®, the same HA used in the present study. Twenty-four women received subperiosteal injections in the retroauricular region, and punch biopsies were performed 4 and 9 months after the injections. The authors noted that type I collagen gradually replaced type III collagen after 9 months of injection [43]. An animal study using Ellansé showed the formation of type III and type I collagen after nine months of biomaterial injection. After 21 months, the predominance of type I collagen deposited around the PCL microspheres suggests that type I collagen replaces type III collagen in the long term, such as in wound healing [20]. Based on these studies, we can deduce that with a more extended observation of the inoculated animals, we would detect a more significant amount of collagen I in our samples.
Our data reinforce literature studies showing the benefits of temporary fillers in maintaining skin volume. Although HA had a more significant volumizing effect, PCL stimulated greater collagen deposition after 30 days compared to HA. This result is reinforced by the higher number of fibroblasts observed in the PCL group. Therefore, we speculate that the greater volumization observed in the HA group is mainly due to its hygroscopic action, an already well-established effect in the literature. Ideally, in applying biocompatible materials, no exacerbated tissue reaction should be adjacent to the injected product. Mild, controlled, subclinical inflammation is expected to prolong the product's longevity. The local response of the tissue to the foreign body, through phagocytosis, is the most critical factor in determining the filler's longevity. In this process, some enzymes are present in the tissue, and free radicals break the filler into fragments that are removed by circulating macrophages and, subsequently, by lymphatic channels [44].